

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 March 2008 (13.03.2008)

PCT

(10) International Publication Number
WO 2008/030382 A1

(51) International Patent Classification:

A61K 31/397 (2006.01) A61P 9/10 (2006.01)
A61K 31/7012 (2006.01) A61P 3/00 (2006.01)
A61P 3/06 (2006.01) A61P 1/16 (2006.01)

(21) International Application Number:

PCT/US2007/019065

(22) International Filing Date: 29 August 2007 (29.08.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/842,211 5 September 2006 (05.09.2006) US

(71) Applicant (for all designated States except US): SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VELTRI, Enrico, P. [US/US]; 6 Toftrees Court, Princeton, New Jersey 08540 (US).

(74) Agents: RUSSELL, Mark W. et al.; Schering Cororation, 2000 Galloping Hill Road, Patent Dept. K-6-1 1990, Kenilworth, New Jersey 07033 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: PHARMACEUTICAL COMBINATIONS FOR LIPID MANAGEMENT AND IN THE TREATMENT OF ATHEROSCLEROSIS AND HEPATIC STEATOSIS

(57) Abstract: A pharmaceutical combination comprising an effective amount of at least one cholesterol absorption inhibitor and at least one microsomal triglyceride transfer protein inhibitor (MTP).



WO 2008/030382 A1

**PHARMACEUTICAL COMBINATIONS FOR LIPID MANAGEMENT AND IN THE
TREATMENT OF ATHEROSCLEROSIS AND HEPATIC STEATOSIS**

RELATED APPLICATIONS

5 This application claims priority to provisional application USSN 60/842,211,
filed on September 5, 2006, herein incorporated by reference.

FIELD OF THE INVENTION

10 The present invention relates to pharmaceutical combinations which are used in lipid
management of a mammal, such as a human, and in the treatment of atherosclerosis
and hepatic steatosis by administering an effective amount of the pharmaceutical
combination. The pharmaceutical combinations comprise at least one cholesterol
absorption inhibitor (CAI) and a microsomal triglyceride transfer protein (MTP)
inhibitor.

15 **BACKGROUND OF THE INVENTION**

Vascular disease is a term which broadly encompasses all disorders of blood
vessels including small and large arteries and veins and blood flow. The most
prevalent form of vascular disease is arteriosclerosis, a condition associated with the
20 thickening and hardening of the arterial wall. Arteriosclerosis of the large vessels is
referred to as atherosclerosis. Atherosclerosis is the predominant underlying factor in
vascular disorders such as coronary artery disease, aortic aneurysm, arterial disease
of the lower extremities and cerebrovascular disease.

25 One major risk factor for arteriosclerosis is high serum cholesterol. A total
cholesterol level in excess of 225-250 mg/dl is associated with significant elevation of
risk of vascular disease, particularly coronary heart disease.

30 Cholesteryl esters are a major component of atherosclerotic lesions and the
major storage form of cholesterol in arterial wall cells. Formation of cholesteryl esters
is also a step in the intestinal absorption of dietary cholesterol. Thus, inhibition of
cholesteryl ester formation and reduction of serum cholesterol can inhibit the
progression of atherosclerotic lesion formation, decrease the accumulation of
cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary
cholesterol.

The regulation of whole-body cholesterol homeostasis in mammals and animals involves the regulation of dietary cholesterol and modulation of cholesterol biosynthesis, bile acid biosynthesis and the catabolism of the cholesterol-containing plasma lipoproteins. The liver is the major organ responsible for cholesterol biosynthesis and catabolism and, for this reason, it is a prime determinant of plasma cholesterol levels. The liver is the site of synthesis and secretion of very low density lipoproteins (VLDL) which are subsequently metabolized to low density lipoproteins (LDL) in the circulation. LDL are the predominant cholesterol-carrying lipoproteins in the plasma and an increase in their concentration is correlated with increased atherosclerosis. When intestinal cholesterol absorption is reduced, by whatever means, less cholesterol is delivered to the liver. The consequence of this action is decreased hepatic lipoprotein (VLDL) production and an increase in the hepatic clearance of plasma cholesterol, mostly as LDL. Thus, the net effect of inhibiting intestinal cholesterol absorption is a decrease in plasma cholesterol levels.

U.S. Patents Nos. 5,846,966 and 5,661,145, respectively, disclose treatments for inhibiting atherosclerosis and reducing plasma cholesterol levels using such hydroxy-substituted azetidinone compounds or substituted β -lactam compounds in combination with HMG-CoA reductase inhibitor compounds, which act by blocking hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase (the rate-limiting enzyme in hepatic cholesterol synthesis). HMG-CoA reductase inhibitors, e.g., statins such as lovastatin, simvastatin, and pravastatin, slow the progression of atherosclerotic lesions in the coronary and carotid arteries. Simvastatin and pravastatin have also been shown to reduce the risk of coronary heart disease events in patients with hypercholesterolemia and/or atherosclerotic coronary heart disease (CHD).

Simvastatin is marketed worldwide, and sold in the U.S. under the tradename ZOCOR®. Methods for making it are described in U.S. Patent Nos. 4,444,784; 4,916,239; 4,820,850; among other patent and literature publications.

U.S. Patent No. 5,698,527 discloses ergostanone derivatives substituted with disaccharides as cholesterol absorption inhibitors, employed alone or in combination with certain other cholesterol lowering agents, which are useful in the treatment of hypercholesterolemia and related disorders.

Other vascular conditions frequently coexist with cholesterol levels associated with atherosclerosis. These may include hypertension, angina and/or arrhythmia.

The relevance of, for example, elevated blood pressure as a risk factor for atherosclerosis, cardiovascular and cerebrovascular disease in both men and women has been clarified in a large number of epidemiological studies.

Clinical trials of blood pressure lowering using cardiovascular agents including, for example, calcium channel blockers, have shown beneficial effects in the treatment of early atherosclerotic lesions (see, e.g., Lichtien, P.R. et al. :Lancet, 335: 1109-1113 (1990) and Waters, D. et al. Circulation 82: 1940-1953 (1990)). Scott (PCT patent Application No. WO 99/11260) describes combinations of an HMG CoA reductase inhibitor with an antihypertensive agent for the treatment of atherosclerosis and other symptoms of vascular disease risk. Additionally, Egon et al. (PCT Patent Application No. WO 96/40255) describe a combination therapy of antihypertensive agents including eplerenone and angiotensin II antagonist for treating cardiovascular disease.

In vitro MTP catalyzes the transport of lipid molecules between phospholipid membranes. See, U.S. 6,472,414 B1. *In vivo* it has been reported that MTP mediates triglyceride absorption and chylomicron secretion from the intestine and VLDL secretion from the liver, by linking lipid molecules with apolipoprotein B (ApoB). (See, abstract of S. Williams & J.D. Best, Expert Opinion on Therapeutic Patents (April 2003, vol.13, no. 4, pp. 470-488), www.expertopin.com/doi/abs/10.1517/13543776.13.4.479?cookieSet+1&journalCode). It follows that inhibition of MTP could reduce the level of all ApoB-containing proteins, including LDL. Drugs that inhibit MTP, therefore, potentially could be effective in reducing atherosclerotic vascular disease by lowering all levels of atherogenic lipoproteins. One commentator has suggested that while partial inhibition of MTP by an inhibitor could be useful when combined with other drugs that alter lipid metabolism, marked inhibition of MTO could cause significant adverse effects (Williams & Best).

Substances that inhibit MTP are well known in the art. See US 2006/0166999 A1 and US 6,472,414 B2, both herein incorporated by reference, which cites to EP 705 831, EP 779 279, EP 779 276, EP 802 198 and EP 799 828, also incorporated by reference. Zaiss et al., *Circulation*, 100 (18 Suppl. I): 255 Abst. 13423 (1999) reports that implitiapipe, a MTP inhibitor, prevents the formation of atherosclerotic plaques in mice.

WO 2005/087234 A1, incorporated by reference, discloses method and compositions for treating hyperlipidemia and/or hypercholesterolemia that comprise

administering to the subject and effective amount of an MTP inhibitor, wherein said administration comprises at least three step-wise, increasing dosages of the MTP inhibitor; the MTP inhibitor may be combined with a further lipid modifying compound, such as a HMG Co-A reductase inhibitor or ezetimibe.

5 WO 00/38725 A1, incorporated by reference, discloses cardiovascular therapeutic combinations including an ileal bile acid transport inhibitor or cholesteryl ester transport protein inhibitor in combination with a fibric acid derivative, nicotinic acid derivative, microsomal triglyceride transfer protein inhibitor, cholesterol absorption antagonist, phytosterol, stanol, antihypertensive agent or bile acid
10 sequestrant.

Despite recent improvements in the management of lipid levels in mammals, such as humans, as well as for the treatment for atherosclerosis, hyperlipidemia, hyperlipenia, hypertriglyceridemia, other vascular diseases and hepatic steatosis, there remains a need in the art for improved compositions and treatments these disease
15 states.

SUMMARY OF THE INVENTION

The present invention provides for pharmaceutical combinations comprising at least one cholesterol absorption inhibitor, e.g., a sterol absorption inhibitor or a 5- α -
20 stanol absorption inhibitor, and at least one microsomal triglyceride transfer protein inhibitor.

The present invention also provides for a method for lipid management in a mammal in need thereof which comprises administering an effective amount of a pharmaceutical combination comprising at least one cholesterol absorption inhibitor,
25 e.g., a sterol absorption inhibitor or a 5- α -stanol absorption inhibitor, and at least one microsomal triglyceride transfer protein inhibitor.

An alternative embodiment of the present invention also provides for a method for the treatment, prevention or ameliorating the symptoms atherosclerosis in a mammal in need thereof by administering an effective amount of a composition
30 comprising at least one cholesterol absorption inhibitor, e.g., a sterol absorption inhibitor, a 5- α -stanol absorption inhibitor, and at least one microsomal triglyceride transfer protein inhibitor.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.